VTX-2337: Clinical Trials

4 trials of VTX-2337, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 4 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 3, Terminated 1
Phase 12Completed 1, Terminated 1

Follow VTX-2337: new trials by email Literature Review of VTX-2337 trials Research Report on VTX-2337

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Durvalumab, Pegylated Liposomal Doxorubicin, Motolimod - Ovarian Cancer
Phase 1 / Phase 2CompletedLudwig Institute for Cancer Research532015-12-022022-10-10
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
VTX-2337, Carboplatin, Cisplatin - Carcinoma, Squamous Cell of Head and Neck
Phase 2CompletedCelgene1952013-10-142019-10-29
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo - Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 2CompletedCelgene2972012-10-312019-09-26
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
VTX-2337 plus radiotherapy - Low Grade B Cell Lymphoma
Phase 1 / Phase 2TerminatedCelgene22011-07-012019-09-25

Conditions studied

Brenner Tumor (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Fallopian Tube Neoplasms (1)  ·  Lymphoma (1)  ·  Ovarian Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

Celgene (3)  ·  Ludwig Institute for Cancer Research (1)

Countries

United States (4)  ·  Switzerland (1)

Top investigators

Amar Patel, MD (3)  ·  Bradley J Monk, MD (1)  ·  Bradley J. Monk, MD (1)  ·  Ezra Cohen, MD (1)  ·  George Coukos, MD, PhD (1)  ·  Robert Ferris, MD, PhD (1)

Results publications

PMID 24807889, PMID 27810904, PMID 28453702, PMID 29931076, PMID 37407274